SPECT with simulation measures dose absorption in non-Hodgkin lymphoma

06/10/2013 | Medscape (free registration)

Findings presented at the SNMMI Annual Meeting showed that for patients undergoing I-131 radioimmunotherapy for non-Hodgkin lymphoma, tumor-absorbed dose may help determine progression-free survival. Researchers employed SPECT/CT imaging and Monte Carlo radiation transport simulation to evaluate 3-dimensional dosimetric parameters. Predicted tumor dose was highly correlated with delivered tumor dose, researchers said. The method, which is also being assessed for measuring bone marrow irradiation, has potential to facilitate personalized treatments.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC